Ozone-high-doses ACC. to Dr. Lahodny and the latest scientific results.
DOI:
https://doi.org/10.7203/jo3t.6.7.2022.25984Resum
Self-funding his own work on the so-called therapeutic effects of medical ozone with respect to its alleged potential impacts on mitochondria and stem cells, he has been focusing since 2010 on an innovative form of ozone therapy called OHT—“Ozonhochdosistherapie”— commonly known as “10 pass” in the USA. Through a specific process involving 10 repeated interactive transits incurred via autohemotherapy, the blood is “fused” with 200 ml of ozone gas respectively brought to a concentration of 70 mcg/ml, thus providing a cumulative ozone intake of 140,000 mcg. The evolution of the ozonotherapeutic treatment promoted by Lahodny would then consist, in a way, in breaking the restrictive rules relating to pragmatic dosage which tended to prevail until now with regard to a usual protocol which still remains well anchored in traditional customs and habits. Indeed, any former procedure usually involved a single injection of ozonated autologous blood therapy containing 200 ml of ozone at a concentration of 40 mcg, after which the session would end. This conceptual limit was based on an arbitrary credo that exceeding this dose boundary—in terms of both quantity and concentration administered—would be likely to result in cell bursting by blood dissolution, a supputive risk whose consequences had previously been considered hypothetically lethal. In 2014, he discovered and refined a new dosage—L1—that he believes would activate the growth of stem cells and the production of adenosine triphosphate (ATP). Its application can be summed up as a major autologous blood therapy combined with massive doses of ozone injections both in terms of concentration — up to 70 mcg/ml in ozon IV or even 80 mcg/ml in rectal insufflation - and quantity: which generally implied 140,000 mcg, but sometimes up to 280,000 mcg in the treatment of more complex conditions. Thanks to this innovative approach, Lahodny claimed to obtain therapeutic results that he described as “exceptional” in the treatment of a number of chronic pathologies as well as several other morbid conditions which are generally considered difficult to treat.Descàrregues
Descàrregues
Publicades
Com citar
-
Resum511
-
PDF 568
Número
Secció
Llicència
Journal of Ozone Therapy applies the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC 4.0) license to works we publish.
Under this license, authors retain ownership of the copyright for their content, but allow anyone to download, reuse, reprint, modify, distribute and/or copy the content as long as the original authors and source are cited. No permission is required from the authors or the publishers.
You may not use the material for commercial purposes.
Appropriate attribution can be provided by simply citing the original article, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.